[Pharmacotherapy of peripheral arteriosclerosis]

Area of Science:

• Vascular Medicine
• Pharmacology

Background:

• Peripheral atherosclerosis significantly impacts patient mobility and quality of life.
• Effective pharmacologic interventions are crucial for managing intermittent claudication and improving limb circulation.

Purpose of the Study:

• To compare the efficacy of pyridinol carbamate, pentoxifylline, cetiedil, and butalamine in treating peripheral atherosclerosis.
• To evaluate the effects of these medications on microcirculation, blood lipids, and blood viscosity.

Main Methods:

• A comparative study involving 178 patients with peripheral atherosclerosis.
• Patients were treated with pyridinol carbamate (90), pentoxifylline (40), cetiedil (30), or butalamine (18) for 2-4 months.
• Efficacy was assessed by objective criteria, including improved tolerance to load and changes in microcirculation, blood lipids, and viscosity.

Main Results:

• Pyridinol carbamate and pentoxifylline (Trental) demonstrated the highest effectiveness in improving intermittent claudication and circulation.
• Pyridinol carbamate positively influenced microcirculation and significantly reduced triglyceride levels.
• Pentoxifylline decreased blood viscosity and platelet aggregation, while cetiedil showed lesser effects on viscosity but reduced erythrocyte aggregation.

Conclusions:

• Pyridinol carbamate and pentoxifylline are superior treatment options for peripheral atherosclerosis, particularly for intermittent claudication.
• The therapeutic benefits of pyridinol carbamate are linked to its dual action on microcirculation and lipid metabolism.
• Further research into the specific mechanisms and comparative long-term outcomes of these agents is warranted.